Public Funding for Storm (Id) LTD.

We are doing developing a solution to identify people who are at risk of developing Osteoporosis (OP). OP is a health condition that weakens bones, making them fragile and more likely to break. It develops slowly over several years and is often only diagnosed when a fall or sudden impact causes a bone to break. We are interested in determining which patients are at risk of developing OP. We will do this by combining different types of data together including data from medical images called CT scans and data from patient's medical records. Using a techinque called machine learning we will develop a way of determining if someone is at risk of developing OP and provide an integrated platform improve the delivery of treatment by clinical teams. Using machine learning to predict which patients are at risk from their images and medical records means that we can prevent fractures by early treatment for OP. This will reduce the risk to patients of life limiting falls and should also reduce hospital admission for surgical management of fractures. We have assembled a multi-disciplinary team consisting of clinicians, data scientists and computer scientists to work together to find a way of identifying at risk patients.

The brief for this challenge was to develop an innovative and collaborative solution to a major healthcare challenge which will grow the UK digital healthcare industry through the innovative use of digital technology. COPD is a serious but treatable and preventable chronic health condition. COPD cannot be cured but optimised management improves symptoms, complications, quality of life and survival. COPD is becoming more common (prevalence increase in UK to 1.4 million by 2030). Disease exacerbations, which have adverse outcomes and often trigger hospital admissions, underpin the rising costs of managing COPD (projected increase in UK to £2.3bn by 2030). The costs and care-quality gap of COPD exacerbations, coupled with the global rising prevalence present a major healthcare challenge, with considerable opportunity for commercial digital health science innovations. Our proposal, which has been developed in partnership with patients, clinicians, enterprise and government representation is to establish a continuous and preventative digital health service model for COPD, integrating the individual COPD management digital innovations which our consortium partners have prototyped and piloted. Our digital technology innovations comprise: - * The **Lenus Health platform** which integrates healthcare information, patient-reported symptoms and remotely monitored data in a clinician dashboard, with patient-clinician communication functionality, clinical care plans and machine learning derived decision support. The patient interface presents monitored data, communication, disease self-management support and curated insights in an empowering patient app. GDPR compliant consent, upscaling and regulatory pathways and connectivity with electronic health records have been established. * **Remote-managed home NIV** (non-invasive ventilation). Home NIV treatment for severe COPD reduces hospital admissions and exacerbations. Remote-management via a cloud-based platform facilitates treatment delivery. The connected hardware acquires continuous monitoring and computer machine-learning of this data stream will improve accuracy and quality of COPD management. By facilitating integration of remote-management to routine care and providing decision support to offset need for experienced input our digital service model will allow UK NHS and global adoption of this intervention. * **Risk-prediction algorithms for COPD outcomes**. The project data-stream will be analysed by computer machine-learning algorithms, allowing increasingly accurate outcome predictions. These will by prospectively presented in the patient and clinician-facing Lenus platform to allow more effective self and clinician management of COPD. This innovative digital health strategy will bridge the care-quality gap and reduce healthcare costs for high-risk COPD patients. The value demonstrated will expand our partners commercially. This project will be an innovation exemplar for other healthcare conditions and other vendors.